TRAW — Traws Pharma Income Statement
0.000.00%
- $10.92m
- -$5.47m
- $0.23m
Annual income statement for Traws Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.18 | 0.231 | 0.226 | 0.226 | 0.226 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 23.9 | 25.2 | 16.7 | 19.9 | 20.5 |
Operating Profit | -21.7 | -25 | -16.5 | -19.6 | -20.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.5 | -25.2 | -16.2 | -19 | -18.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.5 | -25.2 | -16.2 | -19 | -18.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -21.5 | -25.2 | -16.2 | -19 | -18.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.5 | -25.2 | -16.2 | -19 | -18.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -22.4 | -2.17 | -0.96 | -0.907 | -0.903 |